CA2917767C - Cystobactamides - Google Patents

Cystobactamides Download PDF

Info

Publication number
CA2917767C
CA2917767C CA2917767A CA2917767A CA2917767C CA 2917767 C CA2917767 C CA 2917767C CA 2917767 A CA2917767 A CA 2917767A CA 2917767 A CA2917767 A CA 2917767A CA 2917767 C CA2917767 C CA 2917767C
Authority
CA
Canada
Prior art keywords
group
cystobactamide
alkyl
formula
ome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2917767A
Other languages
English (en)
French (fr)
Other versions
CA2917767A1 (en
Inventor
Sascha Baumann
Jennifer HERRMANN
Kathrin MOHR
Heinrich Steinmetz
Klaus Gerth
Ritesh RAJU
Rolf Muller
Mostafa Hamed
Liang Liang Wang
Rolf Hartmann
Walid A. M. Elgaher
Andreas Kirschning
Maria Moreno
Franziska Gille
Stephan HUETTEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Centre for Infection Research
Original Assignee
Helmholtz Centre for Infection Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Centre for Infection Research filed Critical Helmholtz Centre for Infection Research
Publication of CA2917767A1 publication Critical patent/CA2917767A1/en
Application granted granted Critical
Publication of CA2917767C publication Critical patent/CA2917767C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2917767A 2013-07-12 2014-07-14 Cystobactamides Active CA2917767C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13003539 2013-07-12
EP13003539.7 2013-07-12
PCT/EP2014/001925 WO2015003816A2 (en) 2013-07-12 2014-07-14 Cystobactamides

Publications (2)

Publication Number Publication Date
CA2917767A1 CA2917767A1 (en) 2015-01-15
CA2917767C true CA2917767C (en) 2022-05-03

Family

ID=48792948

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2917767A Active CA2917767C (en) 2013-07-12 2014-07-14 Cystobactamides

Country Status (7)

Country Link
US (3) US20160145304A1 (enExample)
EP (1) EP3019615B1 (enExample)
JP (1) JP6730183B2 (enExample)
CN (1) CN105793424B (enExample)
AU (1) AU2014289663B2 (enExample)
CA (1) CA2917767C (enExample)
WO (1) WO2015003816A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2917767C (en) 2013-07-12 2022-05-03 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Cystobactamides
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
US20170204052A1 (en) * 2014-05-15 2017-07-20 Korea Research Institute Of Bioscience And Biotechnology Novel antimicrobial compound and use thereof
CA2968270C (en) * 2014-11-26 2022-11-01 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Further natural cystobactamides, synthetic derivatives thereof, and use thereof in treating bacterial infections
CN105712894A (zh) * 2016-03-23 2016-06-29 叶芳 一种3-甲氧基-4-氨基苯甲酸及其制备方法
WO2018062422A1 (ja) * 2016-09-28 2018-04-05 日産化学工業株式会社 ジアミンおよびその利用
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
AU2018300150A1 (en) 2017-07-11 2020-01-30 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
EP3655394B1 (en) * 2017-07-18 2023-11-22 Technische Universität Berlin Novel albicidin derivatives, their use and synthesis
US11034648B2 (en) * 2017-08-23 2021-06-15 Helmholtz-Zentrum Für Cystobactamide derivatives
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Condensed bicyclic compounds are useful as ubiquitin-specific peptidase 30 inhibitors
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
EP4218934B1 (en) 2018-10-05 2025-06-18 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 30 (usp30)
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
AU2020300619A1 (en) 2019-07-03 2022-01-27 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
EP4313173A4 (en) * 2021-03-31 2025-04-16 MediBeacon Inc. Purification of substituted diaminopyrazine dicarboxylic acids
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
CN113563220B (zh) * 2021-06-25 2023-08-29 华中农业大学 一种抗菌化合物及其应用
CN121712741A (zh) 2023-06-26 2026-03-20 亥姆霍兹感染研究中心有限公司 新型囊菌酰胺衍生物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525354A (en) * 1983-09-14 1985-06-25 University Of Hawaii Antibiotic and process for the production thereof
US7020622B1 (en) * 1997-06-10 2006-03-28 Linkshare Corporation Transaction tracking, managing, assessment, and auditing data processing system and network
FR2772025B1 (fr) 1997-12-10 2000-03-03 Guerbet Sa Chelates metalliques de macrocycles polyaminocarboxyliques et leur application a l'imagerie par resonance magnetique
WO2001083800A2 (en) * 2000-04-28 2001-11-08 Kosan Biosciences, Inc. Heterologous production of polyketides
CA2413702A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceuticals Industries Ltd. Carvedilol
US7510852B2 (en) * 2002-10-18 2009-03-31 Centre De Cooperation Internationale En Recherche Agronomique Pour Le Developpement (Cirad) Biosynthetic genes and host cells for the synthesis of polyketide antibiotics and method of use
WO2006109846A1 (ja) 2005-04-06 2006-10-19 Takeda Pharmaceutical Company Limited トリアゾール誘導体およびその用途
US7758972B2 (en) * 2006-09-26 2010-07-20 Semiconductor Energy Laboratory Co., Ltd. Stilbene derivative, light emitting element, light emitting device, and electronic appliance
JP5379965B2 (ja) * 2006-09-26 2013-12-25 株式会社半導体エネルギー研究所 スチルベン誘導体、発光素子および発光装置
US7816324B2 (en) * 2007-03-13 2010-10-19 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
US8236983B2 (en) * 2008-03-13 2012-08-07 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by apoptosis
US8754124B2 (en) * 2011-11-23 2014-06-17 Board Of Regents, The University Of Texas System Oligo-benzamide compounds and their use in treating cancers
EP2956437B1 (en) * 2013-02-15 2023-05-10 Technische Universität Berlin Albicidin derivatives for the treatment of bacterial infections
CA2917767C (en) 2013-07-12 2022-05-03 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Cystobactamides
US20170204052A1 (en) 2014-05-15 2017-07-20 Korea Research Institute Of Bioscience And Biotechnology Novel antimicrobial compound and use thereof
CA2968270C (en) * 2014-11-26 2022-11-01 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Further natural cystobactamides, synthetic derivatives thereof, and use thereof in treating bacterial infections

Also Published As

Publication number Publication date
CA2917767A1 (en) 2015-01-15
US20160145304A1 (en) 2016-05-26
CN105793424A (zh) 2016-07-20
WO2015003816A2 (en) 2015-01-15
US20190185514A1 (en) 2019-06-20
EP3019615B1 (en) 2021-04-07
CN105793424B (zh) 2021-02-19
US11225503B2 (en) 2022-01-18
US10793600B2 (en) 2020-10-06
JP6730183B2 (ja) 2020-07-29
US20200331964A1 (en) 2020-10-22
EP3019615A2 (en) 2016-05-18
AU2014289663B2 (en) 2019-03-07
AU2014289663A1 (en) 2016-02-04
JP2016527215A (ja) 2016-09-08
WO2015003816A3 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
US11225503B2 (en) Crystobactamides
Degrassi et al. Plant growth-promoting Pseudomonas putida WCS358 produces and secretes four cyclic dipeptides: cross-talk with quorum sensing bacterial sensors
KR100379100B1 (ko) 스트렙토그라민및돌연변이합성에의한이의제조방법
CA2466340C (en) Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical
CN107001241B (zh) 新型孢囊菌酰胺
CA2695813A1 (en) Thiopeptide precursor protein, gene encoding it and uses thereof
AU2005265443A1 (en) DNA coding for polypeptide participating in biosynthesis of pladienolide
EP3309253B1 (en) Genes for biosynthesis of tetracycline compounds and uses thereof
Gromyko et al. Generation of Streptomyces globisporus SMY622 strain with increased landomycin E production and it's initial characterization
HK1229840B (en) Cystobactamides
DK2509950T3 (en) 5-amino-4-hydroxypentoylamides
KR100814098B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 알킬아미노나프탈렌일옥시 메틸옥트 n-하이드록시엔아마이드 유도체,이의 제조방법 및 이를 유효성분으로 하는 항암제용 약학조성물
KR100532356B1 (ko) 스트렙토마이세스 속 균주로부터 유래된 카르바모일 트랜스퍼레이즈의 아미노산서열 및 이를 코딩하는 유전자의 염기서열
CN117642417A (zh) 新型达罗巴汀衍生物
CA2538147A1 (en) Farnesyl dibenzodiazepinone, processes for its production and its use as a pharmaceutical
WO2006045063A2 (en) Heterologous genes for encoding polyketides
KR19990074514A (ko) 아미노글라이코사이드계 항생제에 대해 다제내성을지정하는유전자

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250703

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250703